Pharsight

1. List of Tazverik drug patents

Application	Filing Date	Opposition Party	Legal Status
EP11824247A	2016-11-02	GlaxoSmithKline Intellectual Property (No.2) Limited	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11052093	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (8 years from now)
US9090562	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (8 years from now)
US10821113	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (9 years from now)
US9394283	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (9 years from now)
US8410088	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Jan, 2034 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9175331	EPIZYME INC	Inhibitors of human EZH2, and methods of use thereof	Sep, 2031 (8 years from now)
US9333217	EPIZYME INC	Inhibitors of human EZH2, and methods of use thereof	Sep, 2031 (8 years from now)
US8691507	EPIZYME INC	Inhibitors of human EZH2 and methods of use thereof	Sep, 2031 (8 years from now)
US9334527	EPIZYME INC	Inhibitors of human EZH2, and methods of use thereof	Sep, 2031 (8 years from now)
US9949999	EPIZYME INC	Inhibitors of human EZH2, and methods of use thereof	Sep, 2031 (8 years from now)
US8895245	EPIZYME INC	Inhibitors of human EZH2 and methods of use thereof	Sep, 2031 (8 years from now)
US8765732	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (8 years from now)
US10155002	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (8 years from now)
US9549931	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (8 years from now)
US9855275	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (8 years from now)
US10420775	EPIZYME INC	Aryl-or heteroaryl-substituted benzene compounds	Apr, 2032 (8 years from now)
US9522152	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Apr, 2032 (8 years from now)
US9872862	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (9 years from now)
US11491163	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (9 years from now)
US10245269	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (9 years from now)
US9688665	EPIZYME INC	Methods of treating cancer	Aug, 2034 (11 years from now)
US9889138	EPIZYME INC	Method for treating cancer	Oct, 2035 (12 years from now)
US10369155	EPIZYME INC	Method for treating cancer	Oct, 2035 (12 years from now)
US10786511	EPIZYME INC	Method for treating cancer	Dec, 2035 (12 years from now)

Do you want to check out TAZVERIK patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 23, 2025
New Indication (I)	Jun 18, 2023
Orphan Drug Exclusivity (ODE)	Jan 23, 2027

NCE-1 date: 2024-01-24

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma positive for an...

Dosage: TABLET;ORAL